{
    "nctId": "NCT02458391",
    "briefTitle": "Complete Decongestive Therapy in Breast Cancer-Related Lymphedema",
    "officialTitle": "Therapeutic Quantity of Complete Decongestive Therapy in Breast Cancer-Related Lymphedema: A Double Blinded Randomized Control Trial",
    "overallStatus": "WITHDRAWN",
    "conditions": "Lymphedema of Upper Limb",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Change from baseline in impairments in function, activity limitations, and participation restrictions",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Have active unilateral breast cancer-related lymphedema\n2. Medically stable\n3. Have not participated in lymphedema therapy the past 3 months\n4. An affected limb volume measurement of \\>10% excess volume\n5. Ages 18-95 years old\n\n   * Patients undergoing any medical treatment for their breast cancer diagnosis will be included in this study.\n   * Patients with any stage breast cancer will be included in this study.\n   * Patients with a prior diagnosis of breast cancer, other cancer will be included in this study. There is no minimum time requirement that has prolapsed between their diagnosis and this study.\n\nAll subjects must have given signed, informed consent prior to registration on study.\n\nExclusion Criteria:\n\n1. Prophylactic treatment indicated\n2. A presence of upper extremity wounds present\n3. Active signs of infection or deep vein thrombosis (DVT)\n4. Bilateral lymphedema present\n5. Evidence of contraindications to CDT: uncontrolled hypertension, heart disease including congestive heart failure, and renal insufficiency\n6. Severe lymphedema present as defined by \\> 30% increase in limb volume",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}